TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects up to 10 months old with clinical history of a reaction to cow's milk protein and/or confirmed diagnosis (up to grade II anaphylaxis) of allergy to cow's milk protein by one of the following criteria, within two months prior to the baseline visit are eligible to enter the study:~  * Negative or positive skin prick tests ( fresh milk, rice, casein hydrolysates)~ * Negative or positive specific IgE for cow's milk proteins (alphalactalbumine, betalactoglobuline, caseine and cow's milk)~ * Negative or positive Milk Atopy Patch Test~ * Positive Double Blind Placebo Control Food Challenge (DBPCFC) with cow milk~* Gestational Age 37-42 weeks inclusive~* Apgar SCORE \>7 at 5 minutes~* Singleton birth~* Birth weight ≥2.500 g~* Written informed consent~Exclusion Criteria:~* Previous signs of allergy to any extensively hydrolysed formula~* Confirmed history of acute severe, potentially life threatening reaction after isolated accidental ingestion of cow's milk e.g. history of anaphylactic reaction, graded more or equal to grade III, as this could not be compatible with an allocation to the eHF group~* Daily formula intake \< 100 ml~* Major congenital malformations or neonatal diseases~* Severe concurrent or chronic diseases~* Intrauterine growth retardation~* Neonatal infections ( e.g. CMV, HIV)~* Simultaneous participation in other clinical trials~* Parents not signing written informed consent~* Unable to adhere to protocol requirements or study visits due to non compliance of parents or caregivers.~* Liver, kidney, haematological abnormalities as judged clinically by investigators at baseline.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Months
- Healthy Volunteers: f

Study Arms:
- HRF (Rice formula) (Type: EXPERIMENTAL): Hydrolyzed Rice Protein Formula (HRF)
- eHF (Extensive Hydrolysed Formula) (Type: PLACEBO_COMPARATOR): Extensive Hydrolysed Cow's Milk Protein Formula (eHF)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Spinal Manipulation on Vulvar Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provides written and dated informed consent to participate in the study.~* Is between the ages of 18-40 years.~* Reports pain in the pelvis and/or vestibule (area that is wiped after using the toilet) that has been present for ≥ 6 weeks.~* Has not had treatment for pelvic or vestibule pain in the 6 months prior to study participation.~* Is willing and able to comply with study protocol.~* Is healthy and free from disease, as determined by a health history questionnaire and screening exam.~* Agrees to abstain from alcohol consumption 24 hours prior to the study protocol.~* Reports a consistent regimen of pain medication use in the 6 weeks prior to the study protocol. This includes both prescription and over the counter medications.~* Secondary Inclusion Criteria: demonstrates provoked vestibule pain to q-tip testing.~Exclusion Criteria:~* Is currently pregnant, or attempting to become pregnant, as the intervention is contraindicated for this population.~* Fails the health history, spine screen; or does not demonstrate provoked vestibule pain with q-tip test.~* Has undergone any spine or pelvic girdle surgery in the 12 months prior to the study.~* Has ever had sling/mesh placement to the pelvic region.~* Has been diagnosed with osteopenia, osteoporosis, acute infection or arthritis flare, or other condition that could weaken the bony skeleton.~* Has ever had a thoracic spine fracture.~* Has had a change in any prescription or over-the-counter medications used for pain in the 6 weeks prior to the study.~* Any other condition or adverse event in which study investigator recommend removal from the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Thoracic Manipulation (ThM) (Type: EXPERIMENTAL): Will undergo spinal manipulation between pain assessment pre and post.
- Sham thoracic treatment (ThS) (Type: SHAM_COMPARATOR): Sham manipulation between pain assessment pre and post

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registry to Measure the Impact of Adding Genomic Testing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (\< or equal to 12 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics:~* PSA less than or equal to 10 ng/dl and~* Gleason's 7 (4+3 or 3+4) or Gleason's 6 and~* Age greater than 55 years old and~* Clinical Stage T1 or T2~* Clinically localized (no evidence on clinical or imaging studies of advanced disease).~* No hormonal therapy including luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.~Exclusion Criteria:~- Known history of hypogonadism

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccination in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who receive the scheduled cytotoxic chemotherapy every 3 weeks because of solid cancer.~   Specific definition of each term is like following:~  * The solid cancer includes various kinds of cancer except hematologic and lymphoid malignancies.~  * Cytotoxic chemotherapy includes adjuvant, neoadjuvant or palliative purpose of chemotherapy with the planned duration at least over 3 cycles every 3 weeks.~  * Targeted therapy drugs like as monoclonal antibody, tyrosine kinase inhibitor or oral chemotherapy drugs like as Xeloda are excluded.~2. Patients who did not receive the influenza vaccination yet in the current year.~3. Older than 19 years~4. Eastern Cooperative Oncology Group (ECOG) performance status is 0, 1, or 2~5. Cell blood count meets following criteria:~   * Neutrophile count ≥ 1.5 x 10\^9/L~  * Platelet count ≥ 100 x 10\^9/L~  * Hemoglobin ≥ 8 g/dL~6. Patients who can understand and agreed with the informed consents.~Exclusion Criteria:~1. Patients who have any contraindication for influenza vaccination.~2. Patients who are supposed to receive the last chemotherapy at the enrollment~3. Patients who receive simultaneous radiation therapy with cytotoxic chemotherapy~4. Patients who receive any immunosuppressant (excluding steroid for anti-emetic effect)~5. Patients with HIV and low CD 4+ T cell count (\< 500/uL)~6. Patients with autoimmune disease who are anticipated to have a problem with immunogenicity for vaccine~7. Patients who have transplanted organ and receive immunosuppressants~8. Patients who are supposed to get prophylactic G-CSF after chemotherapy~9. Patients who are suspected to have active infectious disease.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Day 1 vaccination (Type: EXPERIMENTAL): Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts.
- Day 11 vaccination (Type: ACTIVE_COMPARATOR): Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or more~* COVID-19 confirmed by PCR~* Oxygen requirements until 35 % by venturi mask or 5 lt minutes by nasal cannula~* Consent form signed~Exclusion Criteria:~* Previous steroid use 48 hours or more.~* Pregnancy~* Chronic respiratory failure~* Requirements of mechanical ventilation (invasive or no invasive)~* Chronic liver damage Child Pugh B or C~* Chronic kidney disease stage IV or V.~* Immunosuppressed~* Participation on other trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients should be voluntarily sign the written informed consent.~2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic squamous NSCLC. Or recurrent squamous NSCLC according UICC/AJCC 8th edition.~3. At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated could be considered as a target lesion only in the condition that progression occurred at the time of 3 months after the end of radiotherapy.~4. Previously treated with one platinum based regimen (including platinum and endostar regimen) and progression occur during or after treatment or unbearable treatment related adverse events.~5. Progression after EGFR-TKIs in patients with driver gene mutation.~6. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~Exclusion Criteria:~1. Patient who is allergic to recombinant humanized PD-1 monoclonal antibody or the components of the drug.~2. Patient who is allergic to taxane.~3. Previously treated with any of the antibodies targeted on PD-1, PD-L1, PD-2, CD137, CTLA-4, T cell, co-stimulation or drugs targeted on the checkpoint signal pathway.~4. Previously treated with docetaxel.~5. The histopathological subtype is not squamous cell non-small cell lung cancer, or squamous cell \< 90% in a mixed carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SCT-I10A plus Docetaxel (Type: EXPERIMENTAL): SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
- Placebo puls docetaxel (Type: ACTIVE_COMPARATOR): Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
- Maintenance therapy of SCT-I10A (Type: EXPERIMENTAL): Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
- Maintenance therapy of Placebo (Type: PLACEBO_COMPARATOR): Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improve Management of Heart Failure With Procalcitonin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who present to the emergency department (ED) with leading symptom dyspnea~2. Suspected or known heart failure~3. midregional pro atrial natriuretic peptide (MR-proANP)\>300 pmol/L, brain natriuretic peptid (BNP) \>350 ng/ml or N-terminal of the prohormone brain natriuretic peptide (NT-proBNP)\>1800 ng/l~4. Patient has given written Informed Consent within study timelines to allow antibiotic therapy within 8 hours~5. Adult patients (i.e. \>18 years of age)~6. Hospitalization for at least 1 overnight stay planned~Exclusion Criteria:~1. Patient participates in any other interventional clinical trial~2. Trauma related shortness of breath~3. Patient diagnosed with lung or thyroid cancer~4. Known terminal disease with life expectancy of less than 6 months, e.g. advanced metastasized cancer disease~5. Organ transplant requiring immunosuppression~6. Abdominal, vascular or thorax surgery within the last 30 days~7. End stage/advanced heart failure - defined by planned heart transplantation, or cardiogenic shock~8. Female patients who have given birth within 3 months before study enrolment~9. Current use of antibiotics or requirement of immediate antibiotic therapy before randomization and measurement of Procalcitonin~10. End stage renal failure requiring dialysis~11. Patient is not willing, or it is not possible or advisable for the patient, to follow the study schedule, including antibiotic therapy and 90 days follow up~12. Patient has already participated in the clinical trial previously~13. Pregnant or lactating women~14. Patients who are institutionalized by official or judicial order~15. Dependants of the sponsor, the contract research organization (CRO), the study site or the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCT-guided (Type: EXPERIMENTAL): Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended
- Standard of Care (Type: NO_INTERVENTION): Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, age ≥18 years, signed informed consent.~2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~3. Patients must have a life expectancy of at least 3 months.~4. Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary. Failure of at least two-line chemotherapy OR platinum resistant ovarian cancer (defined as relapsing within 6 months after a platinum based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing during a platinum based chemotherapy).~5. Criteria for recurrence or metastasis: blood CA125 is more than 2 times the upper limit of normal value, or imaging findings (CT/MRI/PET-CT) show recurrence or metastasis, or ascites cancer cells are positive.~6. Platinum refractory or resistant criteria: relapse or metastasis within 6 months end of platinum based chemotherapy.~7. The interval time to last chemotherapy was more than 4 weeks.~8. The patient received radiotherapy or surgery for more than 4 weeks, and the wound healed completely.~9. Patients must have adequate organ function as defined by the following criteria: White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.0 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10\^9/L. Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN. Serum creatinine ≤ 1 x ULN~10. The main organs (liver, kidney and heart) function are basically normal.~Exclusion Criteria:~1. Had prior exposure to apatinib or has known allegies to apatinib.~2. History of other malignant tumors (except those with cured basal cell carcinoma and cervical carcinoma in situ).~3. History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.~4. Patients with QT interval prolongation.~5. Inadequately controlled hypertension.~6. Serious, non-healing wound, active ulcer, bowel obstruction.~7. History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1.~8. Evidence of bleeding diathesis or coagulopathy.~9. Patients with positive urine protein.~10. Major surgical procedure within 28 days prior to Day 1.~11. Symptomatic central nervous system (CNS) metastasis.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- apatinib (Type: EXPERIMENTAL): 1 times a day, atapinib, 500 mg, is taken orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Woman, over 18 years old.~2. With non-metastatic breast cancer.~3. Treated by hormone therapy, regardless of the molecule (cancer RH positive).~4. In primary prescription of hormone therapy.~5. First prescription by a medical oncologist, surgeon or radiation therapist from the CGFL.~6. Pharmacy of the patient located in the perimeter defined in the context of the study (Residents in the Burgundy region between a triangle delimited by the towns of Chatillon sur Seine, Dole and Chalon sur Saone.~7. Woman who received information about the study and gave her written consent.~8. Affiliation to a social security scheme.~9. Participant Agreement of the referent city pharmacy of the patient.~Exclusion Criteria:~1. Metastatic patient.~2. Patient participating in another epidemiological or clinical study of adherence and / or hormone therapy.~3. Patient under guardianship, curatorship or safeguard of justice.~4. Patient with severe psychiatric disorders or who does not speak the French language~5. Refusal to participate in the study.~6. Refusal of participation of the referent city pharmacy of the patient.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmaceutical Interview (Type: EXPERIMENTAL): Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Erector Spinae Block Versus Continuous Paravertebral Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I - III status, undergoing unilateral thoracotomy for either esophageal atresia related intrathoracic procedures or other non-cardiac general surgical intrathoracic procedures.~Exclusion Criteria:~* Patients undergoing procedures including pleurodesis, pleural stripping, and decortication or other procedures with widely distributed pleural disruption.~* Patients with severe neurodevelopmental delays.~* Patients with previous chronic pain syndromes.~* Patients with a history of opioid treatment at any point in the 2 months prior to surgery.~* Lack of parental consent and/or child assent.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- continuous erector spinae block (Type: EXPERIMENTAL): An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
- continuous paravertebral block (Type: ACTIVE_COMPARATOR): A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Port Site Pain Following Percutaneous Externally-Assembled Laparoscopic Donor Nephrectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing laparoscopic donor nephrectomy~Exclusion Criteria:~* Patients unwilling to participate in the study~* Patients unfit for laparoscopic surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEAL laparoscopic nephrectomy (Type: EXPERIMENTAL): Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues